CEO Executive AssistantTransplant programs occupy a unique position in the healthcare landscape. They are simultaneously high-acuity clinical service lines, complex regulatory enterprises, and strategically significant institutional assets. A transplant program’s reputation is built over years of consistent outcomes performance and lost in a single adverse regulatory action. The healthcare CEO overseeing transplant services must maintain active oversight of clinical quality, UNOS compliance, organ procurement organization relationships, CMS certification status, and an expanding program portfolio, often while managing the full breadth of a large health system’s operations.
The executive assistant supporting a healthcare CEO in this environment provides far more than scheduling support. They build and maintain the coordination infrastructure through which the CEO exercises consistent, informed oversight of a program where the stakes are unambiguous and the regulatory consequences of inattention are severe.
This article details how skilled executive assistants support healthcare CEOs leading transplant programs across every major operational domain: UNOS compliance briefings, OPO partner coordination, CMS certification management, board presentations, and living donor program development.
Scheduling Transplant Program Leadership Reviews and UNOS Compliance Briefings
The transplant program leadership review is the CEO’s primary mechanism for maintaining direct visibility into program performance. These reviews must cover clinical outcomes data, waitlist management metrics, organ acceptance rates, and compliance status across all active transplant programs (solid organ programs may include kidney, liver, heart, lung, and pancreas, each with its own quality metrics and regulatory thresholds). The executive assistant structures this review cadence so that no performance domain goes unexamined for longer than the CEO can afford.
The EA schedules monthly operational reviews with transplant program medical directors and surgical leadership, quarterly outcomes reviews that assess CMS and UNOS quality metric performance, and ad hoc reviews triggered by a program alert, a MPSC review notification, or an adverse outcome requiring executive engagement. For each review, the EA establishes materials preparation deadlines with the transplant program’s quality and analytics teams, ensuring the CEO receives a comprehensive briefing package rather than a deck assembled the morning of the meeting.
UNOS compliance briefings require a distinct scheduling cadence. The EA maintains a UNOS regulatory calendar that maps every policy update cycle, program review cycle, and membership agreement renewal obligation. When UNOS releases updated membership requirements or policy revisions with operational implications, the EA schedules an urgent briefing with the transplant compliance officer and ensures the CEO understands the required organizational response before the next leadership forum.
Coordinating Compliance Preparation Logistics
When the transplant program is preparing for a UNOS site review or responding to a Membership and Professional Standards Committee (MPSC) inquiry, the coordination demands are substantial. The EA manages the CEO’s participation in preparation meetings, coordinates document collection across clinical, compliance, and quality teams, and tracks the submission deadline for any required written response. These processes have rigid external deadlines. The EA’s milestone tracking ensures nothing slips.
For programs subject to a UNOS performance improvement plan, the EA maintains a separate tracker for plan milestone completion, ensuring the CEO has real-time visibility into corrective action progress and can engage directly when milestones are at risk.
Coordinating CEO Engagement with OPO Partners and Transplant Medical Directors
The organ procurement organization relationship is foundational to transplant program performance. OPO conversion rates, donation after cardiac death (DCD) program coordination, and donor family service quality all directly affect the supply of organs available to the transplant program’s waitlisted patients. The CEO’s relationship with OPO leadership must be active, mutual, and grounded in shared accountability for donation outcomes.
The EA schedules quarterly strategic meetings between the CEO and OPO executive leadership, coordinates annual performance reviews that assess the transplant program’s relationship with its designated OPO service area, and arranges any joint initiatives (DCD program expansion, hospital development outreach, or donation awareness programs) that require CEO-level commitment. For each meeting, the EA compiles a relationship briefing that summarizes recent OPO performance data, any open issues requiring executive resolution, and the agenda priorities the CEO wants to advance.
Transplant medical director engagement requires a parallel coordination structure. Each organ program has a physician medical director who bears primary clinical and regulatory accountability for program performance. The CEO must maintain regular direct engagement with each medical director, both to provide institutional support and to stay informed of clinical developments that carry strategic or regulatory implications. The EA schedules regular one-on-one sessions between the CEO and each transplant medical director, ensuring these conversations happen on a consistent cadence rather than only when problems arise.
Managing Stakeholder Communication Across Organizations
Transplant programs operate within a dense stakeholder network that extends beyond the walls of the transplanting hospital. Referring physicians at community hospitals and specialty practices depend on the transplant program for timely evaluation and listing decisions. The EA manages the CEO’s engagement with key referring physician leaders, scheduling relationship meetings, tracking referral volume trends, and ensuring the CEO is briefed on any referring partner concerns before they escalate into network management problems.
When the CEO needs to communicate directly with a transplant medical director or OPO partner on an urgent clinical or regulatory matter, the EA ensures prompt scheduling and prepares any background materials the CEO needs for an informed, productive conversation.
Managing CMS Certification and MPSC Outcomes Review Meeting Logistics
CMS certification is the regulatory foundation on which transplant program operations rest. Loss of CMS approval terminates the program’s ability to bill Medicare and Medicaid for transplant services, an outcome with immediate and potentially existential financial consequences. The CEO’s oversight of CMS certification status is non-negotiable, and the EA structures the briefing and review schedule accordingly.
The EA maintains a CMS compliance calendar that maps annual outcomes reporting deadlines, monitoring thresholds for each organ program, and any active performance improvement obligations. Against this calendar, the EA schedules pre-submission reviews of annual outcomes data with the quality team, briefings on any program that is approaching a CMS monitoring threshold, and preparation sessions for any CMS site review or desk audit that the program is subject to.
MPSC outcomes reviews are triggered when a transplant program’s outcomes fall below expected performance thresholds as calculated by the Scientific Registry of Transplant Recipients (SRTR). When a program enters MPSC review, the CEO must be immediately and fully engaged. The EA manages the scheduling and logistics of every internal preparation meeting, coordinates external counsel participation where appropriate, and ensures the CEO has comprehensive performance data and a clear understanding of the MPSC process before any regulatory interaction.
Coordinating External Review Logistics
When UNOS or CMS conducts a site review at the transplant program, the logistical demands are significant. The EA coordinates the CEO’s participation in the review process, manages the schedule of meetings between reviewers and clinical and administrative leadership, and ensures that all requested documentation is compiled and available. During the review, the EA serves as the logistical hub, managing room assignments, meal arrangements, document delivery, and communication between the review team and the transplant program’s leadership.
For context on how leading transplant and surgical programs are thinking about quality and program development strategy, analysis from McKinsey on hospital specialization provides useful perspective on how specialty program leadership drives competitive differentiation.
Those structuring CEO oversight of high-acuity clinical service lines should also review how surgical services coordination organizes the CEO’s engagement with surgical program leadership across a complex portfolio.
Preparing Board Presentations on Transplant Volume Growth and Program Expansion Investment
The healthcare CEO presents transplant program performance to the board on a regular cadence, typically at least quarterly. These presentations carry both clinical and strategic dimensions: outcomes quality and regulatory compliance on one hand, volume growth and program expansion investment on the other. The EA manages the full preparation cycle for these presentations, from data collection through final distribution.
The EA establishes internal preparation milestones that work backward from the board meeting date: data finalization, first draft submission, executive review, legal and compliance review (for any materials discussing active regulatory matters), final revision, and board package distribution. Each milestone is tracked by the EA, with escalation to the CEO when a milestone is at risk of slipping.
Transplant board presentations typically address outcomes performance (one-year graft survival rates by organ type, patient survival, waitlist management metrics, and SRTR expected performance comparisons), operational volume (transplants performed by organ type, waitlist additions and removals, living donor evaluations), compliance status (UNOS membership standing, CMS certification status, any active monitoring or MPSC activity), and program development (new organ program feasibility, living donor program expansion, joint venture opportunities with regional transplant centers).
Managing Sensitive Board Communications
Transplant program regulatory matters carry potential legal and reputational sensitivity. When the board presentation includes discussion of an active MPSC review, a CMS performance concern, or an adverse outcome under legal review, the EA coordinates with legal counsel to ensure appropriate handling of those materials: attorney-client privilege markings, restricted distribution, or physical-only distribution rather than electronic board portal posting. The CEO relies on the EA to manage this sensitivity consistently and without prompting.
When the board or a board committee requests supplemental information following a presentation, the EA tracks those requests, assigns responsibility to the appropriate subject matter experts, and ensures responses are delivered before the required follow-up deadline.
Tracking Living Donor Program Development and New Organ Program Launch Milestones
Living donor programs represent one of the most significant growth opportunities available to established transplant centers. A living donor kidney program that achieves strong volume performance can meaningfully expand waitlist access and improve patient outcomes. The development of a living donor program or the expansion of living donor volume requires sustained operational investment and regulatory navigation. The CEO must maintain oversight of this development without losing sight of the existing program’s operational performance.
The EA builds and maintains a living donor program development tracker that covers the key milestone domains: clinical protocol development and approval, living donor advocate program credentialing, UNOS program application and approval, CMS certification for the living donor component, staff recruitment, and first case scheduling. This tracker is updated after each development meeting and reviewed with the CEO on a regular cadence tied to the overall program development timeline.
New organ program launches (adding a heart program to an existing kidney and liver center, for example, or launching a lung program in a market without existing local access) represent even larger development undertakings. The EA structures the milestone tracking for these initiatives to cover the full regulatory approval pathway, capital investment timeline, surgical talent recruitment and credentialing process, program UNOS application, and CMS certification survey preparation. These processes span two to four years in most cases. The EA ensures that the CEO maintains consistent oversight of the timeline without allowing development milestones to fall off the operational calendar.
Coordinating Clinical Research Program Integration
Most high-volume transplant programs operate active clinical research programs, including multi-site clinical trials, SRTR data analysis initiatives, and investigator-initiated studies assessing novel immunosuppression or surgical technique protocols. The CEO may not be directly involved in day-to-day research operations, but they maintain oversight of the research program’s strategic direction, regulatory compliance, and academic partnership relationships.
The EA schedules quarterly research program briefings with the transplant program’s research director, coordinates CEO participation in any investigator meetings or academic partner planning sessions, and ensures the CEO is aware of any research regulatory matters (IRB findings, FDA inspection activity, or trial enrollment concerns) that carry institutional risk.
Those building a comprehensive research and clinical program coordination system should also examine how clinical research coordination structures the CEO’s engagement with academic partners and research leadership across a health system portfolio.
The Coordination Standard That Transplant Programs Require
Transplant programs do not tolerate operational ambiguity at the executive level. Regulatory agencies expect that the CEO can speak with precision to program outcomes performance, compliance status, and corrective action progress. OPO partners expect responsive, engaged executive leadership. The board expects clear-eyed assessment of both performance and risk. Transplant medical directors expect institutional support that is credible and sustained.
The executive assistant who builds the coordination infrastructure described in this article gives the CEO the operational platform needed to meet every one of those expectations. A regulatory calendar that anticipates every compliance obligation, a review cadence that provides consistent leadership visibility, a board preparation workflow that produces high-quality materials on deadline, and a development milestone tracker that ensures nothing falls through: these systems are not administrative conveniences. They are the operational foundation on which a high-performing transplant program is led.
For a healthcare CEO whose professional reputation is directly tied to the quality and integrity of their transplant program, the EA who delivers this coordination standard is among the most valuable members of the executive team.